Study Flow Diagram




Figure 1

Change From Baseline ACQ-6 by Blood Eosinophil Count

EOS		Week 24* (From Interim)				Week 24 (From Stage I)			
	Treatment Group	N	Change from Baseline	Difference	*p*-value	N	Change from Baseline	Difference	*p*-value
<300	Placebo	103	-0.70			103	-0.70		
	2mg	12	-1.50	-0.864	---	12	-1.50	-0.864	---
	20mg	5	-1.00	-0.214	---	5	-1.00	-0.214	---
	100mg	81	-0.79	-0.174	0.230	81	-0.79	-0.174	0.230
≥ 300	Placebo	57	-0.71			57	-0.71		
	2mg	43	-0.86	-0.169	0.367	43	-0.86	-0.169	0.367
	20mg	51	-1.04	-0.486	0.011	51	-1.04	-0.486	0.011
	100mg	74	-1.06	-0.367	0.028	74	-1.06	-0.367	0.028

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 2

WO 2015/023508 PCT/US2014/050122

Change From Baseline ACQ-6 by Blood Eosinophil Count

EOS		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline	Difference	*p*-value	N	Change from Baseline	Difference	*p*-value
<300	Placebo	103	-0.70			60	-0.89		
	2mg	12	-1.50	-0.843	---	7	-1.62	-0.723	---
	20mg	5	-1.00	-0.214	---	5	-2.00	-0.816	---
	100mg	81	-0.79	-0.174	0.230	60	-1.02	-0.221	0.233
≥ 300	Placebo	57	-0.71			38	-0.76		
	2mg	43	-0.86	-0.169	0.367	35	-1.00	-0.339	0.156
	20mg	51	-1.04	-0.486	0.011	35	-1.14	-0.433	0.083
	100mg	74	-1.06	-0.367	0.028	52	-1.26	-0.532	0.015

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 3

Change From Baseline ACQ-6 by Baseline ICS Status

ICS		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline	Difference	*p*-value	N	Change from Baseline	Difference	*p*-value
Medium	Placebo	91	-0.82			58	-1.03		
	2mg	23	-1.00	-0.148	0.479	17	-1.26	-0.173	0.54
	20mg	29	-0.62	0.039	0.839	19	-0.85	0.092	0.725
	100mg	82	-0.89	-0.164	0.227	61	-1.19	-0.310	0.094
High	Placebo	69	-0.54			40	-0.57		
	2mg	32	-0.99	-0.368	0.102	25	-0.99	-0.465	0.062
	20mg	27	-1.49	-0.971	<0.001	21	-1.61	-0.888	0.003
	100mg	74	-0.95	-0.354	0.044	50	-1.06	-0.468	0.039

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 4

Change From Baseline ACQ-6 by Blood Eosinophil Count and Baseline ICS Status

EOS and ICS Status		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline	Difference	*p*-value	N	Change from Baseline	Difference	*p*-value
ICS=Medium EOS < 300	Placebo	58	-0.85			35	-1.12		
	2mg	6	-1.06	-0.18	---	3	-1.94	-0.634	---
	20mg	3	-1.28	-0.01	---	3	-1.83	-0.553	---
	100mg	41	-0.81	-0.12	0.507	30	-1.23	-0.222	0.383
ICS=High EOS < 300	Placebo	45	-0.50			25	-0.58		
	2mg	6	-1.94	-1.54	---	4	-1.38	-0.872	---
	20mg	2	-0.58	-0.65	---	2	-2.25	-1.201	---
	100mg	40	-0.78	-0.24	0.312	30	-0.81	-0.213	0.453

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 5

Change From Baseline ACQ-6 by Eosinophil Count and Baseline ICS Status

EOS and ICS Status		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline	Difference	*p*-value	N	Change from Baseline	Difference	*p*-value
ICS=Medium EOS ≥ 300	Placebo	33	-0.78			23	-0.89		
	2mg	17	-0.99	-0.21	0.431	14	-1.12	-0.189	0.583
	20mg	26	-0.54	0.02	0.926	16	-0.67	0.090	0.751
	100mg	41	-0.98	-0.24	0.264	31	-1.14	-0.334	0.211
ICS=High EOS ≥ 300	Placebo	24	-0.63			15	-0.56		
	2mg	26	-0.77	-0.13	0.624	21	-0.92	-0.530	0.118
	20mg	25	-1.56	-1.03	0.001	19	-1.54	-0.976	0.021
	100mg	33	-1.17	-0.54	0.045	21	-1.43	-0.855	0.024

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 6

ACQ-6 by Eosinophil Count – Week 24

EOS Counts Cutoff	Treatment Group	N	Change from Baseline ACQ6 at W24	Difference	*p*-value
≥150	Placebo**	114	-0.68		
	2 mg	53	-0.092	-0.227	0.150
	20mg	55	-1.02	-0.441	0.006
	100mg**	129	-1.01	-0.311	0.011
<150	Placebo	46	-0.76		
	2 mg	2	-3.00		
	20mg	1	-2		
	100mg	26	-0.51	-0.018	0.943
≥200	Placebo	98	-0.75		
	2 mg	52	-0.094	-0.207	0.191
	20mg	55	-1.02	-0.393	0.015
	100mg	116	-1.05	-0.291	0.025
<200	Placebo	62	-0.62		
	2 mg	3	-2.06		
	20mg	1	-2		
	100mg	39	-0.54	-0.156	0.448

Figure 7A

ACQ-6 by Eosinophil Count – Week 24

EOS Counts Cutoff	Treatment Group	N	Change from Baseline ACQ6 at W24	Difference	*p*-value
≥300	Placebo**	57	-0.71		
	2 mg	43	-0.86	-0.169	0.367
	20mg	51	-1.04	-0.486	0.011
	100mg**	74	-1.06	-0.367	0.028
<300	Placebo	103	-0.70		
	2 mg	12	-1.50		
	20mg	5	-1		
	100mg	81	-0.79	-0.174	0.230
≥400	Placebo	36	-0.88		
	2 mg	30	-0.81	-0.120	0.617
	20mg	42	-1.19	-0.516	0.030
	100mg	45	-1.10	-0.392	0.067
<400	Placebo	124	-0.65		
	2 mg	25	-1.22	0.440	0.044
	20mg	14	-0.60	-0.045	0.866
	100mg	110	-0.85	-0.200	0.114

Figure 7B



Time Course of Mean ACQ6: Change from Baseline to Week 24 in Patients with at Least 300 Eosinophils/µl
Mean Change ACQ
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Weeks
PLACEBO
Benralizumab 20 MG
Benralizumab 2 MG
Benralizumab 100 MG

Figure 8



Time Course of Mean Diary Overall Symptom Score: Change from Baseline to Week 24 in Patients with at Least 300 Eosinophils/µl
Mean Change Overall Symptom Score
0.0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
0
2
4
6
8
10
12
14
16
18
20
22
24
Weeks
PLACEBO
Benralizumab 2 MG
Benralizumab 20 MG
Benralizumab 100 MG

Figure 9

Time Course of Mean AQLQ: Change from Baseline to Week 24 in Patients with at Least 300 Eosinophils/µl




Figure 10